Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.66
- Piotroski Score 3.00
- Grade Buy
- Symbol (LTRN)
- Company Lantern Pharma Inc.
- Price $3.04
- Changes Percentage (2.7%)
- Change $0.08
- Day Low $2.80
- Day High $3.11
- Year High $11.99
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.62
- Trailing P/E Ratio -3.44
- Forward P/E Ratio -3.44
- P/E Growth -3.44
- Net Income $-15,961,534
Income Statement
Quarterly
Annual
Latest News of LTRN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...
Lantern Pharma's CEO, Panna Sharma, discusses progress on trials and collaborations. Updates include expansion in Asia, new collaborations, interest in partnerships for the never smoker trial, and the...
By Yahoo! Finance | 1 week ago -
Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire
A list of promising penny stocks includes Lantern Pharma Inc. (NASDAQ:LTRN), a biotech company focusing on AI in drug development. With four hedge funds holding stakes, it ranks 10th on the list for p...
By Yahoo! Finance | 2 months ago
